Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot phase II, open-label, multicenter, efficacy and safety study of 852A administered intravenously to subjects with unresectable metastatic cutaneous melanoma.

Trial Profile

Pilot phase II, open-label, multicenter, efficacy and safety study of 852A administered intravenously to subjects with unresectable metastatic cutaneous melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs 852A (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms 852A-IV-NA-LI-04-MC-M
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top